An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

BACKGROUND. Recent data support the hypothesis that combining lapatinib and trastuzumab with taxane chemotherapy may offer added clinical benefit to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). This study examined the safety of the triplet co...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Esteva, Francisco J., Franco, Sandra X., Hagan, Maura K., Brewster, Abenaa M., Somer, Robert A., Williams, Will, Florance, Allison M., Turner, Simon, Stein, Steven, Perez, Alejandra
Формат: Artigo
Язык:Inglês
Опубликовано: AlphaMed Press 2013
Предметы:
Breast Cancer
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4063391/
https://ncbi.nlm.nih.gov/pubmed/23697602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0129
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы